Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model.
Soheila Asoudeh MoghanlooMohsen ForouzanfarMojtaba JafariniaMohammad Reza FazlollahiGholam Ali KardarPublished in: Immunity, inflammation and disease (2023)
The use of present available recombinant proteins is considered a viable, cost-effective, and long-term option for providing effective HDM allergy immunotherapy vaccines without side effects.